How long does a Botox (onabotulinum toxin A) injection into the lower esophageal sphincter last in patients with achalasia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Duration of Botox Injection Effect in Achalasia

Botox injection for achalasia typically lasts 6-12 months, with most patients experiencing symptom relief for an average of 8-9 months before relapse occurs.

Expected Duration of Effect

The therapeutic effect of botulinum toxin injection into the lower esophageal sphincter is temporary and limited in duration:

  • Initial response: Approximately 70-93% of patients achieve immediate symptom improvement 1, 2, 3
  • Average duration: The effect lasts for a median of 8-9 months in most patients 4, 2
  • Range: Symptom relief can persist anywhere from 2-14 months after a single injection 2
  • Long-term remission: Only about 34-41% of initial responders remain symptom-free beyond one year without requiring repeat injection 1, 5

Relapse Patterns

Nearly 60-70% of patients who initially respond will experience symptomatic relapse within 2 years 1. When relapse occurs:

  • Median time to relapse: Approximately 468 days (15.6 months) after the first injection 4, 3
  • Second injection: Can be performed with reasonable success, though duration may be similar or slightly shorter (10.5 months average) 1
  • Subsequent injections: Efficacy tends to diminish with repeated treatments, with only 50% responding to a second injection 1

Predictors of Longer Duration

Certain patient characteristics are associated with better and more sustained response:

  • Age >50-55 years: Elderly patients demonstrate significantly better long-term outcomes 5, 4, 3
  • Lower baseline LES pressure: Patients with LES pressure not exceeding 50% above normal limits respond better 4
  • Vigorous achalasia: 100% response rate versus 52% in classic achalasia 3

Clinical Implications

Botox should be considered a temporizing measure rather than definitive therapy for achalasia. The 2020 ASGE guideline 6 and 2017 AGA expert reviews 7 position botulinum toxin as primarily appropriate for:

  • High-risk surgical candidates
  • Elderly patients who may not tolerate more invasive procedures
  • Bridge therapy while awaiting definitive treatment

Important caveat: While guidelines discuss POEM and other definitive therapies extensively 8, 7, they consistently note that botox provides only short-term relief and is not considered a durable long-term solution for most achalasia patients.

Monitoring After Injection

Following botox injection, reassess symptoms at 3-6 months to determine if repeat injection is needed when symptoms recur 1, 5. Younger patients (<50 years) with high baseline LES pressures should be counseled that they are less likely to achieve sustained benefit and may be better candidates for pneumatic dilation or myotomy 4.

References

Research

Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2003

Research

Long-term follow-up of achalasic patients treated with botulinum toxin.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2000

Research

Long-term follow-up of achalasia patients treated with botulinum toxin.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002

Research

ASGE guideline on the management of achalasia.

Gastrointestinal endoscopy, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.